Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Single-Cell Long-Read Sequencing Enables the Dissection of BTK Subclonal Dynamics in CLL Treatment

Gage Black, Xiaomeng Huang, Yi Qiao, Philip Moos, Deborah M. Stephens, Gabor Marth, Jennifer A. Woyach

Blood (2023) 142 (Supplement 1): 1893.

https://doi.org/10.1182/blood-2023-179425

Published: 2023

Journal Articles

Clonal Dynamics of ASM-AHN with Avapritinib Treatment

Xiaomeng Huang, Jonathan M. Ahmann, Opal S. Chen, Yi Qiao, Anthony D. Pomicter, Gabor T. Marth, Tracy I. George, Michael W. Deininger

Blood (2022) 140 (Supplement 1): 6737–6738.

https://doi.org/10.1182/blood-2022-167701

Published: 2022

Journal Articles

Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients

Gage S. Black, Xiaomeng Huang, Yi Qiao, Szabolcs Tarapcsak, Kerry A. Rogers, Shrilekha Misra, John C. Byrd, Gabor T. Marth, Deborah M. Stephens, Jennifer A. Woyach

Blood (2022) 140 (4): 401–405.

https://doi.org/10.1182/blood.2021015132

Published: 2022

Includes: Supplemental data

Journal Articles

ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model

Chi-Ling Chiang, Swagata Goswami, Frank W. Frissora, Zhiliang Xie, Pearlly S. Yan, Ralf Bundschuh, Logan A. Walker, Xiaomeng Huang, Rajeswaran Mani, Xiaokui M. Mo, Sivasubramanian Baskar, Christoph Rader, Mitch A. Phelps, Guido Marcucci, John C. Byrd, L. James Lee, Natarajan Muthusamy

Blood (2019) 134 (5): 432–444.

https://doi.org/10.1182/blood.2018882290

Published: 2019

Includes: Supplemental data

Journal Articles

Tumor Antigen ROR1 Targeted Delivery of MiR-29b in Chronic Lymphocytic Leukemia Induces Epigenetic Reprograming Resulting in Cell Cycle Arrest

Chi-Ling Chiang, MS, Swagata Goswami, MS, Rajeswaran Mani, DVM,PhD, Frank Frissora, MS, Zhiliang Xie, Xiaomeng Huang, PhD, Sivasubramanian Baskar, PhD, Christoph Rader, PhD, Mitch A. Phelps, PhD, Guido Marcucci, MD, John C. Byrd, MD, James L. Lee, PhD, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 4981.

https://doi.org/10.1182/blood.V130.Suppl_1.4981.4981

Published: 2017

Journal Articles

Persistence of Somatic Mutation Spectrum and Clonal Architecture in Chronic Myelomonocytic Leukemia Treated with Hypomethylating Agents

Hein Than, MD FRCPath, MRCP, Yi Qiao, PhD, Xiaomeng Huang, PhD, Dongqing Yan, Jamshid Sorouri Khorashad, MD PhD FRCPath, Anthony D. Pomicter, MS, Anca Franzini, PhD, Tibor Kovacsovics, Thomas O'Hare, PhD, Gabor T. Marth, DSc, Michael W. Deininger, MD PhD

Blood (2017) 130 (Supplement 1): 2527.

https://doi.org/10.1182/blood.V130.Suppl_1.2527.2527

Published: 2017

Journal Articles

Immunoliposomal Delivery of Mir-29b By Targeting Tumor Antigen ROR1 Induces Epigenetic Reprograming in Human-ROR1-Expressed Mouse Model of Chronic Lymphocytic Leukemia

Chi-Ling Chiang, Frank W Frissora, Zhiliang Xie, Xiaomeng Huang, Rajeswaran Mani, DVM, Sivasubramanian Baskar, Christoph Rader, Kenneth K. Chan, Guido Marcucci, MD, John C. Byrd, MD, L. James Lee, Natarajan Muthusamy, DVM, PhD

Blood (2015) 126 (23): 1743.

https://doi.org/10.1182/blood.V126.23.1743.1743

Published: 2015

Journal Articles

Implications of the miR-10 family in chemotherapy response of NPM1 -mutated AML

Violaine Havelange, Parvathi Ranganathan, Susan Geyer, Deedra Nicolet, Xiaomeng Huang, Xueyan Yu, Stefano Volinia, Steven M. Kornblau, Michael Andreeff, Carlo M. Croce, Guido Marcucci, Clara D. Bloomfield, Ramiro Garzon

Blood (2014) 123 (15): 2412–2415.

https://doi.org/10.1182/blood-2013-10-532374

Published: 2014

Includes: Supplemental data

Journal Articles

A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b

Hongyan Wang, PhD, Ramasamy Santhanam, Ph.D, Zhiliang Xie, MD, Xiaomeng Huang, Ming Chiu, Mitch A. Phelps, PhD, Alison R Walker, MD, Michael A. Caligiuri, MD, Ramiro Garzon, MD, James Lee, PhD, Natarajan Muthusamy, DVM, Ph.D, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2013) 122 (21): 3933.

https://doi.org/10.1182/blood.V122.21.3933.3933

Published: 2013

Journal Articles

Targeting Mir-155 via The NEDD8-Activating Enzyme Inhibitor MLN4924: A Novel Therapeutic Approach For Acute Myeloid Leukemia (AML)

Jihane C Khalife, MS, Hanna S Radomska, PhD, Jennifer Saultz, MD, Ramasamy Santhanam, PhD, Xiaomeng Huang, Hongyan Wang, PhD, John P. Curfman, Yue-Zhong Wu, MS, Pia Hoellerbauer, Houda Alachkar, PharmD, PhD, Adrienne M Dorrance, Ph.D, Michael A. Caligiuri, MD, Ramiro Garzon, MD, Jason H. Mendler, MD, PhD, Guido Marcucci, MD

Blood (2013) 122 (21): 3804.

https://doi.org/10.1182/blood.V122.21.3804.3804

Published: 2013

Journal Articles

Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML).

Blood (2012) 120 (21): 2422.

https://doi.org/10.1182/blood.V120.21.2422.2422

Published: 2012

Journal Articles

Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML)

Xiaomeng Huang, Sebastian Schwind, MD, Bo Yu, Ph.D, Jiuxia Pang, Ramasamy Santhanam, Ph.D, Kenneth K. Chan, Ph.D, Ramiro Garzon, MD, William Blum, MD, Clara D. Bloomfield, MD, Shujun Liu, Ph.D, Danilo Perrotti, MD, Ph.D, Robert J. Lee, Ph.D, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D, L. James Lee, Ph.D, Guido Marcucci, MD

Blood (2011) 118 (21): 81.

https://doi.org/10.1182/blood.V118.21.81.81

Published: 2011

NARROW

Single-Cell Long-Read Sequencing Enables the Dissection of BTK Subclonal Dynamics in CLL Treatment

Clonal Dynamics of ASM-AHN with Avapritinib Treatment

Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients

ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model

Tumor Antigen ROR1 Targeted Delivery of MiR-29b in Chronic Lymphocytic Leukemia Induces Epigenetic Reprograming Resulting in Cell Cycle Arrest

Persistence of Somatic Mutation Spectrum and Clonal Architecture in Chronic Myelomonocytic Leukemia Treated with Hypomethylating Agents

Immunoliposomal Delivery of Mir-29b By Targeting Tumor Antigen ROR1 Induces Epigenetic Reprograming in Human-ROR1-Expressed Mouse Model of Chronic Lymphocytic Leukemia

Implications of the miR-10 family in chemotherapy response of NPM1 -mutated AML

A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b

Targeting Mir-155 via The NEDD8-Activating Enzyme Inhibitor MLN4924: A Novel Therapeutic Approach For Acute Myeloid Leukemia (AML)

Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML).

Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only